V. Charlton-Menys

发表

Proteinuria and severe mixed dyslipidemia associated with a novel APOAV gene mutation.

R. Hegele, I. Roberts, H. Soran, 2010, Journal of clinical lipidology.

The role of hydrostatic pressure in foam cell formation upon exposure of macrophages to LDL and oxidized LDL.

P. Durrington, V. Charlton-Menys, C. E. Evans, 2008, Atherosclerosis.

Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes

H. Soran, P. Durrington, M. Elseweidy, 2010, Diabetes & vascular disease research.

Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis.

S. O’Rahilly, D. Lomas, P. Murgatroyd, 2009, The Journal of clinical investigation.

Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)

G. Hitman, D. Demicco, D. Betteridge, 2009, Diabetologia.

Squalene Synthase Inhibitors

P. Durrington, V. Charlton-Menys, V. Charlton-menys, 2003, Drugs.

Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).

G. Hitman, D. Demicco, D. Betteridge, 2009, Clinical chemistry.

The robustness of the Roche 2nd generation homogenous HDL cholesterol (PEGME) method: assessment of the effect of serum sample storage for up to 8 years at -80 degrees C.

Yifen Liu, P. Durrington, V. Charlton-Menys, 2007, Clinica chimica acta; international journal of clinical chemistry.

Variation in paraoxonase-1 activity and atherosclerosis

H. Soran, P. Durrington, V. Charlton-Menys, 2009, Current opinion in lipidology.

Concurrent Oral 7 – Rheumatoid Arthritis: Clinical Aspects [OP48–OP53] OP48. The Risk of Non-Melanoma Skin Cancer in Patients Receiving Anti-TNF Therapies for Rheumatoid Athritis: Results from the British Society for Rheumatology Biologics Register

W. Dixon, I. Bruce, G. Kingsley, 2010 .

Small dense LDL is more susceptible to glycation than more buoyant LDL in Type 2 diabetes.

P. Pemberton, H. Soran, P. Durrington, 2013, Clinical science.

Apolipoproteins AI and B as therapeutic targets

P. Durrington, V. Charlton-Menys, V. Charlton-menys, 2006, Journal of internal medicine.

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

G. Hitman, D. Demicco, D. Betteridge, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Indices of Obesity and Cardiovascular Risk Factors in British Women

S. Humphries, G. Lowe, P. McElduff, 2008, Obesity Facts.

Adiponectin in umbilical cord blood is inversely related to low-density lipoprotein cholesterol but not ethnicity.

P. McElduff, N. Bansal, P. Clayton, 2006, The Journal of clinical endocrinology and metabolism.

The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease

G. Hitman, D. Demicco, C. Stehouwer, 2011 .

Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes

G. Hitman, A. Neil, D. Demicco, 2011, Diabetes.

Glycation as an atherogenic modification of LDL

H. Soran, P. Durrington, M. Elseweidy, 2008, Current opinion in lipidology.

Adiponectin and lipid profiles compared with insulins in relation to early growth of British South Asian and European children: the Manchester children's growth and vascular health study.

S. Anderson, I. Gemmell, N. Bansal, 2011, The Journal of clinical endocrinology and metabolism.

Lipoprotein glycation in atherogenesis

H. Soran, P. Durrington, V. Charlton-Menys, 2009 .

Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury

S. Stringer, M. Mamas, L. Neyses, 2013, Front. Physiol..

Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro.

H. Soran, P. Durrington, V. Charlton-Menys, 2009, Atherosclerosis.

Human cholesterol metabolism and therapeutic molecules

P. Durrington, V. Charlton-Menys, V. Charlton-menys, 2007, Experimental physiology.

Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients

H. Soran, P. Durrington, V. Charlton-Menys, 2011, Annals of clinical biochemistry.

Use of the TLX ultracentrifuge for the isolation of different density lipoproteins and effects of freeze/thawing of human plasma before ultracentrifugation

P. Durrington, V. Charlton-Menys, Jelena Chobotova, 2008, Clinical chemistry and laboratory medicine.

High-density lipoprotein impedes glycation of low-density lipoprotein

S. Hama, P. Pemberton, H. Soran, 2013, Diabetes & vascular disease research.

Decorin GAG Synthesis and TGF-&bgr; Signaling Mediate Ox-LDL–Induced Mineralization of Human Vascular Smooth Muscle Cells

S. Stringer, D. Aeschlimann, Jianyun Yan, 2011, Arteriosclerosis, thrombosis, and vascular biology.

Apolipoprotein A5 and hypertriglyceridemia.

P. Durrington, V. Charlton-Menys, V. Charlton-menys, 2005, Clinical chemistry.

Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate.

Yifen Liu, P. Durrington, V. Charlton-Menys, 2006, Clinical chemistry.

Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women.

P. McElduff, P. Pemberton, P. Durrington, 2006, Maturitas.

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

John H Fuller, G. Hitman, D. Betteridge, 2004, The Lancet.

Human cholesterol metabolism and therapeutic molecules

P. Durrington, V. Charlton-Menys, Valentine Charlton-Menys, 2007 .

Alstrom syndrome (OMIM 203800): a case report and literature review

Robert A Hegele, Henian Cao, R. Hegele, 2007, Orphanet journal of rare diseases.

Sequencing of the reannotated LMNB2 gene reveals novel mutations in patients with acquired partial lipodystrophy.

R. Hegele, H. Cao, N. Rodger, 2006, American journal of human genetics.

A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease

Tricia Smith, V. Charlton-Menys, I. Mohan, 2007, Platelets.

Increased C‐reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women’s Heart Study (UKWHS)

W. D. Ashton, S. Humphries, G. Lowe, 2009, Clinical endocrinology.

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a) [S]

M. Caulfield, G. Hitman, A. Stanton, 2012, Journal of Lipid Research.

Genome-wide association study of genetic determinants of LDL- c response to atorvastatin therapy: importance of Lp(a)

G. Hitman, A. Stanton, A. Neil, 2012 .

Molecular characterization of two patients with severe LCAT deficiency.

S. Bertolini, L. Calabresi, P. Durrington, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double‐blind placebo‐controlled trial of high‐ vs. low‐dose atorvastatin 1

M. Gittins, P. Durrington, V. Charlton-Menys, 2011, Diabetic medicine : a journal of the British Diabetic Association.

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial

G. Hitman, D. Demicco, C. Stehouwer, 2015, Diabetologia.

Familial hypobetalipoproteinemia due to a novel early stop mutation.

R. Hegele, C. Packard, M. Caslake, 2008, Journal of Clinical Lipidology.

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

G. Hitman, A. Mcguire, D. Betteridge, 2007, Diabetologia.

Familial hypercholesterolaemia commonly presents with Achilles tenosynovitis

P. Durrington, E. Benbow, V. Charlton-Menys, 2005, Annals of the rheumatic diseases.

Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.

P. Durrington, V. Charlton-Menys, V. Charlton-menys, 2007, Drugs.